|
Regression model predicting variability in response rates in placebo groups of clinical trials; n = 153 studies/comparisons; formal and diagnostic variables (ICD coding) |
|||
| Beta |
t (DFs = 142) |
p-value |
|
|
|
|||
| Constant |
2.07 |
0.04 |
|
| Duration in months |
0.31 |
6.17 |
<0.000001 |
| Multicenter trial |
0.13 |
3.04 |
0.003 |
| Quality Index |
0.18 |
3.44 |
0.0008 |
| Neoplasms (C) |
-0.21 |
-5.48 |
<0.000001 |
| Organical psychological disorders (F0) |
-0.12 |
-3.24 |
0.001 |
| Disorders due to substance abuse (F1) |
-0.14 |
-2.97 |
0.003 |
| Nervous diseases (G) |
-0.10 |
-2.55 |
0.01 |
| Prevention trial |
0.44 |
7.94 |
<0.000001 |
| Quality rating: Additional treatment described? |
-0.21 |
-4.34 |
0.00003 |
| Quality rating: Dropouts described? |
-0.16 |
-3.33 |
0.001 |
Walach et al. BMC Medical Research Methodology 2005 5:26 doi:10.1186/1471-2288-5-26 |
|||